Aspirin / dipyridamole Pregnancy and Breastfeeding Warnings
Aspirin / dipyridamole is also known as: Aggrenox
Aspirin / dipyridamole Pregnancy Warnings
Aspirin-dipyridamole has been assigned to pregnancy category D by the FDA. Aspirin use in pregnancy has been associated with alterations in both maternal and fetal hemostasis. In addition, high doses have been associated with increased perinatal mortality, intrauterine growth retardation, and teratogenic effects. Animal studies with dipyridamole failed to reveal evidence of teratogenicity. Dipyridamole has been given throughout pregnancy in patients requiring anticoagulation for prosthetic heart valve as well as for the prevention of preeclampsia and intrauterine growth retardation. No malformations have been reported associated with perinatal use of dipyridamole. NSAID use during the third trimester of pregnancy should be avoided due to effects on the fetal cardiovascular system (closure of the ductus arteriosus). Increased maternal bleeding can occur during delivery when aspirin is used 1 week prior to and/or during labor and delivery. Prolonged gestation and labor have been reported due to aspirin's inhibition of prostaglandin. Aspirin-dipyridamole is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk. In 1990, the FDA issued a warning that it is especially important not to use aspirin during the last trimester of pregnancy unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.
Aspirin / dipyridamole Breastfeeding Warnings
Aspirin and dipyridamole are excreted into human milk in small amounts. Peak milk salicylate levels have been reported at nine hours after maternal dosing (and measured at 1.1 mg/dL). Use of high doses of aspirin can result in rashes, platelet abnormalities, and bleeding in nursing infants. The manufacturer recommends that caution be used when administering aspirin-dipyridamole to nursing women.
- aspirin/dipyridamole extended-release capsules Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.